) announced the Empowered Genome Community, a noble initiative
meant to help people who have had their genomes sequenced through
efforts such as the Harvard's Personal Genome Project (PGP) and
Understand Your Genome (UYG) program.
At a time, when the medical community needs more innovative and
technologically advanced devised ways and means, to cater to the
challenging needs of the healthcare industry, the Empowered
Genome Community of QIAGEN brings a new leash of hope for the
common people as well as researchers.
The first-of-its-kind in the bio science industry, this community
intends to help those who have had their genomes sequenced,
share, explore and interpret data among themselves as well as
with researchers. This is made possible through QIAGEN's secure
online genome interpretation application, Ingenuity Variant
Analysis. It is a powerful HIPAA-compliant cloud-based solution
that can compare and interpret human genomes to help researchers
understand diseases and other phenotypes.
The core of this interpretation resource is the Ingenuity
Knowledge Base, the leading expert-curated knowledge resource for
next generation biology.
To showcase the utility of the Empowered Genome Community, QIAGEN
released an open collaborative analysis of myopia in 111 people
whose genomes were sequenced through Harvard's PGP. QIAGEN
scientists implemented Variant Analysis to compare the whole
genomes of 111 PGP participants surveyed for eye diseases.
The study revealed that 46 genes were enriched with rare,
potentially functionally relevant variants in people with myopia,
but not those without the condition. Further filtering using
Variant Analysis and significant insights from Ingenuity
Knowledge Base showed that 17 of these genes demonstrate
characteristics related to eyes found in people or mice, or
directly interact with such genes.
The company is soon planning to invite an open collaboration till
Jan 31, 2014, to build a pool of data on human genomes that will
help to strengthen its expertise on myopia physiology,
epidemiology, and filtering strategies. Substantial contributions
recognized by joint authorship on any resulting publication will
also be welcome.
QIAGEN believes the Empowered Genome Community has the potential
to contribute meaningfully to the study of genomes. This
revolutionary knowledge platform can go a long way in the
bioscience industry enabling researchers and scientists to spark
new insights from its data and findings.
The Empowered Genome Community also carries forward the noble
mission taken up by public sequencing efforts like the PGP,
aiding better understanding of important phenotypes like
QGEN currently carries a Zacks Rank #2 (Buy). Other stocks that
are worth a look include
Alexion Pharmaceuticals, Inc.
), each carrying a Zacks Rank #1 (Strong Buy), and
) carrying a Zacks Rank #2 (Buy).
AGENUS INC (AGEN): Free Stock Analysis Report
ACTELION LTD (ALIOF): Get Free Report
ALEXION PHARMA (ALXN): Free Stock Analysis
QIAGEN NV (QGEN): Free Stock Analysis Report
To read this article on Zacks.com click here.